Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice.
Lipopolysaccharide (LPS)-binding protein (LBP) has been shown to regulate the response of monocytes to LPS in vitro. In a previous study, polyclonal anti-LBP IgGs were found to protect D-galactosamine-sensitized mice against a lethal endotoxemic shock induced by a low challenge of LPS or lipid A when administered simultaneously with endotoxin. In the present study, we investigated the mode of action of these anti-LBP IgGs. In vitro, we demonstrated that they interfere with LPS binding to monocytes or polymorphonuclear cells in different ways: by the mere prevention of binding of LPS to LBP thus preventing the binding of LPS to CD14, or by reacting with LPS-LBP complexes thus mediating their binding to complement or Fc receptors on monocytes and on polymorphonuclear cells. In vivo, we demonstrated that anti-LBP IgGs afforded protection against lethal endotoxemic shock by one of two mechanisms. First, LBP blockade by pretreatment with anti-LBP IgG allowed protection against a low dose of LPS (100 ng). This protection occurred despite LPS levels in blood similar to those in control mice but in the absence of detectable tumor necrosis factor (TNF). This demonstrated that anti-LBP IgG could block the LBP-mediated TNF release upon LPS challenge. In contrast, anti-LBP IgG did not afford protection in mice not sensitized with D-galactosamine and challenged with high-dose LPS (1 mg), confirming that LPS at high concentrations could stimulate cells independently of the LBP pathway. Second, anti-LBP treatment administered simultaneously with LPS challenge protected mice against both low and high doses of LPS. Unlike after pretreatment with anti-LBP IgG, this protection was accompanied by a decrease of circulating LPS, suggesting that anti-LBP IgG in these conditions facilitated clearance of LPS probably by clearing LPS-LBP complexes. These data and the fact that LBP binds to all LPS through lipid A suggest that antibody directed to LBP could be a candidate for therapeutic strategies in endotoxemic shock.
Gallay
P
P
Department of Internal Medicine, CHUV-1011 Lausanne, Switzerland.
Heumann
D
D
Le Roy
D
D
Barras
C
C
Glauser
M P
MP
D000209:Acute-Phase Proteins / Q000276:immunology; D000818:Animals; D015415:Biomarkers / Q000097:blood; D002352:Carrier Proteins / Q000276:immunology*; D004731:Endotoxins / Q000633:toxicity; D005260:Female; D005688:Galactosamine / Q000633:toxicity; D007074:Immunoglobulin G / Q000494:pharmacology / Q000627:therapeutic use*; D008050:Lipid A / Q000633:toxicity; D008070:Lipopolysaccharides / Q000378:metabolism / Q000633:toxicity*; D008562:Membrane Glycoproteins; D051379:Mice; D008815:Mice, Inbred Strains; D009000:Monocytes / Q000378:metabolism; D009504:Neutrophils / Q000378:metabolism; D012772:Shock, Septic / Q000517:prevention & control*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D000099231:Lipopolysaccharide-Binding Protein
D000209:Acute-Phase Proteins; D015415:Biomarkers; D002352:Carrier Proteins; D004731:Endotoxins; D005688:Galactosamine; D007074:Immunoglobulin G; D008050:Lipid A; D008070:Lipopolysaccharides; D008562:Membrane Glycoproteins; D014409:Tumor Necrosis Factor-alpha; D000099231:Lipopolysaccharide-Binding Protein